| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2006 | US20060014951 4-amino-substituted pyrimidine derivatives |
| 01/19/2006 | US20060014948 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals |
| 01/19/2006 | US20060014945 Sulfonamides |
| 01/19/2006 | US20060014939 Novel C6-substituted furanoid sugar amino acids and improved process for preparing the same |
| 01/19/2006 | US20060014930 Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 01/19/2006 | US20060014839 Combination of angiotensin II receptor blocker and beta-blocker for secondary prevention of myocardial infarction |
| 01/19/2006 | US20060014838 Process for converting trans-sertraline to cis-sertraline |
| 01/19/2006 | US20060014837 Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug |
| 01/19/2006 | US20060014836 e.g. 1-(Benzofuran-2-carbonyl-3-(3-phenoxy-phenyl)-thiourea;viricides; hepatitis virus |
| 01/19/2006 | US20060014835 Therapeutic agent for chronic obstructive pulmonary disease |
| 01/19/2006 | US20060014834 For treatment of skin disorders (acne); solubilized in alcohol |
| 01/19/2006 | US20060014833 Bioavailability, water solubility |
| 01/19/2006 | US20060014832 Highly pure bases of 3,3-dipheyl propylamine monoesters |
| 01/19/2006 | US20060014831 e.g. 2-[(2-methoxyphenyl)(1-naphthyl)methyl]malononitrile; antiinflammatory and hypoglycemic agent; rheumatoid arthritis, osteoarthritis, psoriatic and juvenile arthritis, inflammatory bowel disease, Crohn's disease, ulcerative and indeterminate colitis, psoriasis, asthma, hyperlipidemia |
| 01/19/2006 | US20060014830 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS |
| 01/19/2006 | US20060014829 Methods for reducing hospitalizations related to heart failure |
| 01/19/2006 | US20060014828 Compositions and methods related to heart failure |
| 01/19/2006 | US20060014827 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia |
| 01/19/2006 | US20060014826 Dioxocyclohexane carboxylic acid phenyl amide derivatives for modulating voltage-gated potassium channels and pharmaceutical compositions containing the same |
| 01/19/2006 | US20060014825 Novel k99-5278 substance and a process for producing the same |
| 01/19/2006 | US20060014824 Strontium ranelate for use in the treatment of gastro-duodenal pain and especially gastritis and duodenitis and any inflammation of the mucosa of the stomach whether acute or chronic |
| 01/19/2006 | US20060014823 Method for the purification of liponic acid |
| 01/19/2006 | US20060014822 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system |
| 01/19/2006 | US20060014821 Inhibitors of SARS 3C like protease |
| 01/19/2006 | US20060014820 N-arachidonoyl-D-alanine; dysfunctional lipid metabolism, insulin sensitivity, glucose homeostasis, and/or inflammation, HIV, and type II diabetes |
| 01/19/2006 | US20060014819 Crystal of (2R,4R)-monatin potassium salt and sweetener composition containing same |
| 01/19/2006 | US20060014818 and luteinizing hormone releasing hormone receptor antagonist; non-peptide; metabolic stability; oral bioavailability; 4-chlorobenzyl {1-[3-(1-carbamoyl-2-methylpropylcarbamoyl)-6,8-dichloro-2,3,4,9-tetrahydro-1H-carbazol-3-ylcarbamoyl]-2-methylpropyl}carbamate; neurodegeenerative diseases, HIV, AIDS |
| 01/19/2006 | US20060014817 CCK-1 receptor modulators |
| 01/19/2006 | US20060014816 such as: 3-{5-[3-(2-methoxyethoxy)-1-propynyl]-3-thienyl}-6-[(4-methyl-1-piperazinyl)methyl]-1,4-dihydroindeno[1,2-c]pyrazole; diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease |
| 01/19/2006 | US20060014815 Process for making pyrazole compounds |
| 01/19/2006 | US20060014814 reacting 3-bromomethyl-1,2-benzisoxazole and ammonium sulfite in an alcohol and water mixture, to obtain a nonhygroscopic and anhydrous 1,2-benzisoxazole-3-methanesulfonic acid ammonium salt; converting a 1,2-benzisoxazole-3-methanesulfonic acid ester to 1,2-benzisoxazole-3-methanesulfonamide |
| 01/19/2006 | US20060014813 Pharmaceutical compounds that regenerate in vivo |
| 01/19/2006 | US20060014812 Use of estrogen related receptor-modulating aryl ethers |
| 01/19/2006 | US20060014811 Medicament for treatment of cancer |
| 01/19/2006 | US20060014809 Substituted triazoles as modulators of PPAR and methods of their preparation |
| 01/19/2006 | US20060014807 Neuroprotective small organic molecules, compositions and uses related thereto |
| 01/19/2006 | US20060014804 Cyanoguanidine prodrugs |
| 01/19/2006 | US20060014803 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics |
| 01/19/2006 | US20060014802 1-aryl-4-cyclopropylpyrazoles with at least one fluorine attached to the cyclopropyl ring; parasiticides; fleas; Extended duration of action for at least 28 days |
| 01/19/2006 | US20060014801 Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
| 01/19/2006 | US20060014800 Naphthalene derivatives and active compounds; interactions between the compounds and certain amino acid residues in the binding pocket of the Retinoid Nuclear receptors; interact with cellular receptors; useful in modulation of gene expression; enhanced in vitro profiles compared to known compounds |
| 01/19/2006 | US20060014799 of isomeric ratios omeprazole mixtures |
| 01/19/2006 | US20060014798 Forming compounds with oxidation using hydrogen peroxide to form sulfur oxide for antisecretory agents of gastric juice |
| 01/19/2006 | US20060014797 [2-(2-Dimethylamino-ethyl)-benzo[b]thiophen-3-yl]-(4-fluoro-phenyl)-methanone; for inhibiting one or more histamine receptors, such as the histamine H1 receptor; improved selectivity, a quicker onset of action, a shorter half-life and/or the ability to penetrate the CNS |
| 01/19/2006 | US20060014796 Epothilone derivatives |
| 01/19/2006 | US20060014795 S-(-) -amlodipine nicotinate and process for the preparation thereof |
| 01/19/2006 | US20060014794 CXCR1 and CXCR2 chemokine antagonists |
| 01/19/2006 | US20060014793 Process and diastereomeric salts useful for the optical resolution of racemic alpha-(4-(1, 1-dimethylethyl) phenyl] -4- (hydroxydiphenylmethyl) -1-piperidinebutanol and derivative compounds |
| 01/19/2006 | US20060014792 Heterocyclo inhibitors of potassium channel function |
| 01/19/2006 | US20060014791 Process for manufacturing of chiral lobelin |
| 01/19/2006 | US20060014790 Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors |
| 01/19/2006 | US20060014789 Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders |
| 01/19/2006 | US20060014788 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/19/2006 | US20060014787 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 01/19/2006 | US20060014786 Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| 01/19/2006 | US20060014785 Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| 01/19/2006 | US20060014784 Compounds for the treatment of metabolic disorders |
| 01/19/2006 | US20060014783 Sulfonylamino-acetic acid derivatives |
| 01/19/2006 | US20060014782 Use of pde iv inhibitors to treat angiogenesis |
| 01/19/2006 | US20060014781 Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| 01/19/2006 | US20060014780 Nicotinamide derivatives useful as PDE4 inhibitors |
| 01/19/2006 | US20060014779 3-Aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake |
| 01/19/2006 | US20060014778 (+-)-cis 6-Methoxy-8-phenyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,4-c]quinoline; serotonin receptor modulators; obesity, diabetes, atherosclerosis, dyslipidemia; central nervous system diseases like anxiety, depression, OCD, panic disorder, psychosis, schizophrenia, sleep and sexual disorders, |
| 01/19/2006 | US20060014777 Pyrrolo(oxo)isoquinolines as 5HT ligands |
| 01/19/2006 | US20060014776 Antitumoral compounds |
| 01/19/2006 | US20060014775 Treatment of psychostimulant addiction |
| 01/19/2006 | US20060014774 1-allyl ergot alkaloid derivatives, methods for producing the same and the use thereof for preventing and treating migraine |
| 01/19/2006 | US20060014773 ATP and/or creatine phosphate synthesis promoter, free radical scavenger, membrane function supporter, cortisol action down regulator and antiapoptotic agent; brain and neurological function support |
| 01/19/2006 | US20060014772 Phenanthroindolizidine alkaloids |
| 01/19/2006 | US20060014771 Quaternizing a tertiary N-substituted morphinan alkaloid substrate such as naltrexone with an alkylating agent such as methyl bromide in an anhydrous aprotic dipolar solvent; separating a 3-alkoxymorphinan from a 3-hydroxymorphinan by forming a salt of the hydride with a strong base and precipitating it. |
| 01/19/2006 | US20060014770 Therapeutic compound and treatments |
| 01/19/2006 | US20060014769 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
| 01/19/2006 | US20060014768 Antiproliferative, anticancer, antitumor agents; rheumatism; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]-phenyl}-acetamide; a p15, and/or a protein inducing action, and/or an MEK inhibitory action; side effect reduction |
| 01/19/2006 | US20060014767 Heterocyclic antiviral compounds |
| 01/19/2006 | US20060014766 Reacting with sodium hydroxide then calcium chloride to form calcium salt derivative; 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors |
| 01/19/2006 | US20060014765 For therapy of, for example, transplant rejection, inflammatory bowel syndrome, rheumatoid arthritis, psoriasis, restenosis, allergic asthma, Alzheimer's disease, Parkinson, stroke, osteoporosis, cancer, and benign hyperplasia |
| 01/19/2006 | US20060014764 Immunosuppressants; autoimmune diseases; antiinflammatory agents;antiarthritic agents; aids |
| 01/19/2006 | US20060014763 Methods for altering mRNA splicing and treating familial dysautonomia and other mechanistically related disorders |
| 01/19/2006 | US20060014762 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives |
| 01/19/2006 | US20060014761 Compounds, compositions and methods |
| 01/19/2006 | US20060014760 Compounds and methods of use to treat infectious diseases |
| 01/19/2006 | US20060014759 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(2,6-dimethylbenzyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid; asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke |
| 01/19/2006 | US20060014758 Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor |
| 01/19/2006 | US20060014757 Method for the treatment of anorexia nervosa |
| 01/19/2006 | US20060014756 Benzimidazoles |
| 01/19/2006 | US20060014755 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/19/2006 | US20060014754 Methods and compositions for treating diseases and conditions of the eye |
| 01/19/2006 | US20060014753 Sigma ligands for neuronal regeneration and functional recovery |
| 01/19/2006 | US20060014752 Heterocyclic anti-epileptogenic agents and methods of use thereof |
| 01/19/2006 | US20060014751 2-Amino-5-formyl-substituted, e.g., 2-[p-(cyclopropylaminocarbonyl)phenyl]-5-formyl-8-isopentyl--7-methyl-5,6,7,8-tetrahydropteridine; treating cancer; infections; inflammatory, cardiovascular, nephrological, neurodegenerative and autoimmune diseases; chemotherapy-induced alopecia and mucositis |
| 01/19/2006 | US20060014750 Pharmaceutical compositions for the treatment of CNS and other disorders |
| 01/19/2006 | US20060014749 (R)-2-{4-[(1H-Indol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol; effective against both gramnegative and grampositive bacteria |
| 01/19/2006 | US20060014748 2-NH-heteroarylimidazoles with antibacterial activity |
| 01/19/2006 | US20060014747 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents |
| 01/19/2006 | US20060014746 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands |
| 01/19/2006 | US20060014745 Pyrrolotriazine compounds |
| 01/19/2006 | US20060014744 Midazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic |
| 01/19/2006 | US20060014743 Methods of preventing bacterial infections with florfenicol-type antibiotics |
| 01/19/2006 | US20060014742 Amide derivative |
| 01/19/2006 | US20060014741 Synthetic process, and crystalline forms of a pyrrolotriazine compound |